The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Long‐term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re‐treatment
Abstract
Objective: Current treatments for systemic lupus erythematosus (SLE) and vasculitis contribute to mortality and incapacity and are only partially effective; thus, newer therapies are clearly needed. Depletion of B cells has led to disease control in patients with autoimmune disorders. We sought to assess the long‐term efficacy and safety of a B cell–depleting therapy in patients with SLE and patients with vasculitis. Methods: In a prospective study with a median followup of 24 months, 11 patients with active or refractory SLE and 11 patients with active or refractory antineutrophil cytoplasmic antibody–associated vasculitis (AAV) received a course of therapy with rituximab (an anti‐CD20 monoclonal antibody) along with a single dose of intravenous cyclophosphamide. Results: Remission followed rapid B cell depletion, with response rates of 100% among the 11 patients with SLE (6 patients had a complete response, and 5 patients had a partial response) and 91% among the 11 patients with AAV (9 patients had a complete response, and 1 patient had partial remission). A renal response occurred in all 6 patients with lupus nephritis. Clinical improvement was accompanied by significant reductions in the daily dose of prednisolone. Relapse occurred in 64% of the patients with SLE and in 60% of those with AAV. B cell return preceded relapse in the majority of patients, and further treatment with rituximab proved effective. IgG and IgM levels were maintained in the normal range. The incidence of infective complications was low; however, infusion reactions were common, and human antichimeric antibodies developed in 5 of 14 patients. Conclusion: B cell depletion offers the prospect of sustained disease remission and improved disease control combined with low toxicity in patients with active or refractory SLE or AAV. Relapse following treatment is common, but re‐treatment is rapidly effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Self-citationBirmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Competence and competition: the challenge of becoming a long-lived plasma cell
Radbruch, A., Muehlinghaus, G., Luger, E. O., Inamine, A., Smith, K. G. C., Dörner, T., & Hiepe, F. (2006) · Nature Reviews Immunology · doi:10.1038/nri1886 · Cited by 1,030
Self-citationLifetime of plasma cells in the bone marrow
Manz, R. A., Thiel, A., & Radbruch, A. (1997) · Nature · doi:10.1038/40540 · Cited by 862
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Chan, O. T. M., Hannum, L. G., Haberman, A. M., Madaio, M. P., & Shlomchik, M. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1639 · Cited by 698
Serreze, D. V., Chapman, H. D., Varnum, D. S., Hanson, M. S., Reifsnyder, P. C., Richard, S. D., Fleming, S. A., Leiter, E. H., & Shultz, L. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.2049 · Cited by 583
An open study of B lymphocyte depletion in systemic lupus erythematosus
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 576
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 543
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J. C. W., & Cambridge, G. (2001) · Rheumatology · doi:10.1093/rheumatology/40.2.205 · Cited by 523
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
Keogh, K. A., Wylam, M. E., Stone, J. H., & Specks, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20718 · Cited by 450
Smith, K. G. C. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.2996 · Cited by 446
Self-citationHoyer, B. F., Moser, K., Hauser, A. E., Peddinghaus, A., Voigt, C., Eilat, D., Radbruch, A., Hiepe, F., & Manz, R. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040168 · Cited by 440
B Cell-Driven Lymphangiogenesis in Inflamed Lymph Nodes Enhances Dendritic Cell Mobilization
Angeli, V., Ginhoux, F., Llodrà, J., Quemeneur, L., Frenette, P. S., Skobe, M., Jessberger, R., Merad, M., & Randolph, G. J. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.003 · Cited by 424
Sfikakis, P. P., Boletis, J., Lionaki, S., Vigklis, V., Fragiadaki, K., Iniotaki, A. G., & Moutsopoulos, H. Μ. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20858 · Cited by 410
Rituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial
Keogh, K. A., Ytterberg, S. R., Fervenza, F. C., Carlson, K. A., Schroeder, D. R., & Specks, U. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1144oc · Cited by 399
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R., & Isenberg, D. A. (2005) · Rheumatology · doi:10.1093/rheumatology/kei080 · Cited by 364
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 345
The phenotype and fate of the antibody‐forming cells of the splenic foci
Smith, K. G. C., Hewitson, T. D., Nossal, G. J. V., & Tarlinton, D. M. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260226 · Cited by 344
Self-citationThe central and multiple roles of B cells in lupus pathogenesis
Chan, O. T. M., Madaio, M. R., Shlomchik, M. J., Chan, O. I. M., Madaio, M. P., & Shlomchik, M. J. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01310.x · Cited by 281
ERIKSSON, P. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01494.x · Cited by 232
Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells
Cassese, G., Lindenau, S., de Boer, B., Arce, S., Hauser, A., Riemekasten, G., Berek, C., Hiepe, F., Krenn, V., Radbruch, A., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200109)31:9<2726::aid-immu2726>3.0.co;2-h · Cited by 228
Pathogenic Roles of B Cells in Human Autoimmunity
Martin, F., & Chan, A. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00112-8 · Cited by 224
(1988) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068256 · Cited by 218
Investigation of the Role of B-Cells in Type 1 Diabetes in the NOD Mouse
Wong, F. S., Wen, L., Tang, M., Ramanathan, M., Visintin, I., Daugherty, J., Hannum, L. G., Janeway, C. A., & Shlomchik, M. J. (2004) · Diabetes · doi:10.2337/diabetes.53.10.2581 · Cited by 205
O’Neill, S. K., Shlomchik, M. J., Glant, T. T., Cao, Y., Doodes, P. D., & Finnegan, A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3781 · Cited by 186
Treatment of lupus nephritis: A meta-analysis of clinical trials
Bansal, V. K., & Beto, J. A. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90029-9 · Cited by 162
B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus
Marks, S. D., Patey, S., Brogan, P. A., Hasson, N., Pilkington, C., Woo, P. M., & Tullus, K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21351 · Cited by 144
B cells as therapeutic targets for rheumatic diseases
Looney, R. J., Anolik, J. H., & Sanz, I. (2004) · Current Opinion in Rheumatology · doi:10.1097/00002281-200405000-00003 · Cited by 115
From BILAG to BLIPS—disease activity assessment in lupus past, present and future
Isenberg, D. A., & Gordon, C. (2000) · Lupus · doi:10.1191/096120300672904669 · Cited by 109
William, J., Euler, C. W., & Shlomchik, M. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6879 · Cited by 95
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy
Weide, R., Heymanns, J., Pandorf, A., & Köppler, H. (2003) · Lupus · doi:10.1191/0961203303lu449cr · Cited by 85
B cell depletion in autoimmune disease.
Gorman, C., Leandro, M. J., & Isenberg, D. A. (2003) · Arthritis Research · doi:10.1186/ar1007 · Cited by 57
Renal vasculitis--an update in 2004
Booth, A. D., Pusey, C. D., & Jayne, D. R. W. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh318 · Cited by 30
Self-citationLong‐Lived Plasma Cells in Immunity and Inflammation
Hauser, A. E., Muehlinghaus, G., Manz, R. A., Cassese, G., Arce, S., Debes, G. F., Hamann, A., Berek, C., Lindenau, S., Doerner, T., et al. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb06059.x · Cited by 28
Cited by
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Self-citationRovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,409
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Dass, S., Bowman, S. J., Vital, E. M., Ikeda, K., Pease, C. T., Hamburger, J., Richards, A., Rauz, S., & Emery, P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083865 · Cited by 431
Metadata
- Authors
- Smith, K. G. C., Jones, R. B., Burns, S. M., & Jayne, D. R. W.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-08-31
- Volume
- 54
- Issue
- 9
- Pages
- 2970-2982
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2011557149
- Cited by
- 400
- References
- 40
- FWCI
- 33.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.